\
&
Contact us
\
&
Contact us
Horizon Europe is the 9th Framework Programme for Research and Innovation of the European Commission and will run from 2021 until 2027. It’s different funding schemes are set out in work programmes containing competitive calls for proposals.
The Digital Europe programme promotes digitalisation in the EU by fostering the update of digital technologies by businesses, citizens and public administration and enhancing digital skills of the workforce. It focuses on the deployment of digital technologies.
Horizon Europe calls for proposals are open to any legal entity, private or public, profit or non-profit. The programme offers both mono-beneficiary and multi-beneficiary opportunities. In the latter case, calls for proposals mostly aim at consortia of at least 3 partners established in a different participating country. More details can be found in the Horizon Europe General Annexes to the work programme. There are exceptions to the rules. Always consult the specific conditions in the call topic.
Digital Europe offers mostly multi-beneficiary actions and is also open to a wide range of public & private stakeholders. Detailed information on who can participate is available in the work programmes and call documents.
Whereas Horizon Europe is a key instruments to implement Europe’s strategy for international cooperation, Digital Europe is more restricted in its possibilities for cooperation for reasons of security strategic autonomy of the EU. Find out more in the infosheet ‘Restrictions in partners that apply for Digital Europe projects’.
NCP Flanders organises information sessions on a regular basis about different aspects of the programmes. Consult the event calendar for upcoming events and/or browse past events for useful information materials.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
